HomeCompareICCT vs PFE

ICCT vs PFE: Dividend Comparison 2026

ICCT yields 400000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICCT wins by $5.011119029548644e+32M in total portfolio value
10 years
ICCT
ICCT
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full ICCT calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ICCT vs PFE

📍 ICCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICCTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICCT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICCT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICCT
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ICCT beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICCT + PFE for your $10,000?

ICCT: 50%PFE: 50%
100% PFE50/50100% ICCT
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ICCT
No analyst data
Altman Z
-53.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICCT buys
0
PFE buys
0
No recent congressional trades found for ICCT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICCTPFE
Forward yield400000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.011119029548644e+32M$49.6K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$5.010957816668433e+32M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ICCT vs PFE ($10,000, DRIP)

YearICCT PortfolioICCT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$40,010,700$40,000,000.00$9,153$693.39+$40.00MICCT
2$149,615,521,729$149,572,710,280.37$8,593$849.25+$149615.51MICCT
3$522,880,052,725,200$522,719,964,116,949.25$8,336$1,066.78+$522880052.72MICCT
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$8,437$1,384.80+$1707862989289.04MICCT
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$9,013$1,875.40+$5213509402845684.00MICCT
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$10,306$2,680.72+$14874219058409543680.00MICCT
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$12,820$4,101.38+$3.966119623405075e+22MICCT
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$17,673$6,826.70+$9.88384363503273e+25MICCT
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$27,543$12,591.86+$2.302052364743449e+29MICCT
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$49,560$26,258.71+$5.011119029548644e+32MICCT

ICCT vs PFE: Complete Analysis 2026

ICCTStock

iCoreConnect Inc., a cloud-based software and technology company, provides Health Insurance Portability and Accountability Act (HIPAA) compliant cloud-based software as a service (SaaS) in the United States. The company's products include iCoreRx, a HIPAA compliant electronic prescription software; iCorePDMP, a solution that checks the patient's Prescription Drug Monitoring Program (PDMP) history before prescribing controlled substances; iCoreVerify and iCoreVerify+, a HIPAA compliant SaaS solution that automatically retrieves a patients insurance eligibility breakdown to verify their benefits in advance of their appointment and on-demand; iCoreHuddle and iCoreHuddle+, a tool to instantly reveal the revenue potential of each patient; and iCoreCodeGenius, a medical coding reference SaaS solution. It also offers iCoreExchange, a SaaS email solution that allows doctors to send and receive secure email with attachments to and from other healthcare professionals; iCoreCloud, ability to backup their on-premise servers and computers to the cloud; iCoreClaims, for processing and managing claims submitted by policyholders or dental care providers; iCorePay, a patient payment processing solutions for payment and revenue cycle tracking; iCoreSecure, secure SaaS solution that solves privacy concerns in the insurance, real estate, financial and many other industry sectors; and iCoreIT, an IT managed services. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. iCoreConnect Inc. was founded in 1992 and is headquartered in Ocoee, Florida.

Full ICCT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ICCT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICCT vs SCHDICCT vs JEPIICCT vs OICCT vs KOICCT vs MAINICCT vs JNJICCT vs MRKICCT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.